MedWatch

Zealand Pharma: ”We’re not looking for a needle in a haystack”

According to executive David Solomon Zealand Pharma has the development of a very specific drug in mind in connection with the company’s collaboration deal with an American partner.

Foto: Zealand Pharma/PR

He can’t discuss the specific details, but David Solomon does reveal that the newly agreed deal with American Protagonist Therapeutics has been signed with the development of a very specific drug in mind.

“We can’t disclose any details, but we are already working with one specific peptide sequence that we are targeting our efforts towards, which is highly important in the treatment of significant, humane diseases. For patent reasons I can’t say what that drug will be.”

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier